Tests chemotherapy and radiation before surgery for localized pancreatic cancer
Tests two chemotherapy drugs plus radiation before surgery in adults with pancreatic cancer.
Key facts
- Who runs it
- Loma Linda University
- Where
- Loma Linda, United StatesSee the site
- Trial code
- Registry title
- Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 30 people, planned
- Started
- 17 Jul 2019
- Expected to end
- Oct 2027
- Type of study
- Interventional
- Treatments tested
- Gemcitabine 1000 mg
- nab-paclitaxel
- Stereotactic Body Radiation Therapy
- Record updated
- 10 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with pancreatic cancer that is still in one place and can possibly be removed by surgery, and who have not had treatment for it yet.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Adenocarcinoma of the pancreas, proven by cell or tissue testing. The tumor is localized and potentially removable by surgery.
- Earlier treatment
- No earlier treatment for pancreatic cancer.
Main reasons for not taking part
- Borderline resectable or metastatic disease
- Another cancer in the last 5 years (some exceptions)
- Active infection that is not controlled and needs treatment through the body
- Pregnant or breast-feeding
- ECOG performance status other than 0 or 1
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Cytologic or histologic proof of adenocarcinoma of the pancreas
- Localized, potentially resectable tumors
- Greater or equal to 18 years of age
- ECOG performance status of 0 or 1
- Adequate hematologic, renal and hepatic function as defined by:
- ANC greater or equal to 1,500 cells/mm3
- Platelets greater or equal to 100,000 cells/mm3
- Serum bilirubin ≤ 1.5 x upper limit of normal (ULN)
- Serum creatinine ≤ 2 x ULN • ALT ≤ 5 x ULN
- AST ≤ 5 x ULN
- No history of prior therapy for pancreatic cancer
- No history of active infection requiring IV antibiotics at the start of study treatment
- Non-pregnant and non-breast-feeding
Who cannot take part
- Patient has borderline resectable or metastatic disease
- History of malignancy in the last 5 years other than in situ cancer or basal or squamous cell skin cancer or malignancies cured by surgery alone or surgery plus radiotherapy and have been continuously disease-free for at least 5 years
- Patient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
Where in United States
- Loma Linda University HealthLoma Linda, United StatesContact: Naveenraj Solomon, MDTaking people
About the trial
What the trial wants to find out
The purpose of this phase 2 research study is to determine whether a combination of chemotherapy drugs plus radiation therapy, given before surgery in resectable pancreactic cancer, can help to increase the chances of surgeons achieving and R0 resection. The chemotherapy drugs used are gemcitabine and nab-paclitaxel. These drugs are both approved by the FDA for use in treating adults with pancreatic adenocarcinoma. The investigational portion of this study is providing the chemotherapy drugs and radiation therapy before surgery. Primary Endpoint, R) resection rate ≥70%. Secondary Endpoints, Disease free survival, Overall survival , Perioperative mortality and morbidity.
The group in the trial
- Chemotherapy and SBRTTreatment being tested
Pre-Operative Chemotherapy: Within 28 days of study enrollment, subjects will receive a combination of Gemcitabine and Nab-paclitaxel for a maximum of four 28-day cycles. Gemcitabine 1000 mg/m2 IV on Days 1,8,15. Nab-paclitaxel 125 mg/m2 on Days 1,8,15. Post-Operative Chemotherapy: Within 5-10 weeks after surgery, subjects will receive a combination of Gemcitabine and Nab-paclitaxel for a maximum of two 28-day cycles. Gemcitabine 1000 mg/m2 IV on Days 1,8,15. Nab-paclitaxel 125 mg/m2 on Days 1,8,15. Standard Stereotactic Body Radiation Therapy (SBRT) fractionation of 6 Gy per day will be used for all patients to a total dose of 30 Gy.
Treatment: Gemcitabine 1000 mg, nab-paclitaxel, and Stereotactic Body Radiation Therapy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase II Trial of Pre-operative Chemotherapy (With Gemcitabine and Nab- Paclitaxel) and Stereotactic Body Radiotherapy Followed by Surgery and Chemotherapy in Patients With Resectable Pancreatic Adenocarcinoma
- Plain-language title
- Tests chemotherapy and radiation before surgery for localized pancreatic cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 10 November 2026